NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis $1.94 +0.02 (+1.04%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$1.98 +0.04 (+1.80%) As of 06/17/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mangoceuticals Stock (NASDAQ:MGRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mangoceuticals alerts:Sign Up Key Stats Today's Range$1.88▼$2.0450-Day Range$1.38▼$2.5752-Week Range$1.32▼$7.66Volume144,054 shsAverage Volume213,125 shsMarket Capitalization$10.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Read More… Mangoceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreMGRX MarketRank™: Mangoceuticals scored higher than 9% of companies evaluated by MarketBeat, and ranked 885th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Mangoceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mangoceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mangoceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMangoceuticals has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.65% of the float of Mangoceuticals has been sold short.Short Interest Ratio / Days to CoverMangoceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mangoceuticals has recently increased by 96.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMangoceuticals does not currently pay a dividend.Dividend GrowthMangoceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.65% of the float of Mangoceuticals has been sold short.Short Interest Ratio / Days to CoverMangoceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mangoceuticals has recently increased by 96.30%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News SentimentMangoceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mangoceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MGRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mangoceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mangoceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of Mangoceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.72% of the stock of Mangoceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mangoceuticals' insider trading history. Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MGRX Stock News HeadlinesMangoceuticals Strengthens Position with Equity TransactionsJune 10, 2025 | tipranks.comMangoceuticals files to sell 4.46M shares of common stock by selling shareholdersMay 30, 2025 | msn.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.June 18, 2025 | Paradigm Press (Ad)Mangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 29, 2025 | finanznachrichten.deMangoceuticals, Inc. Reports 100% Survival Rates in Field Studies of MGX-0024 for Poultry Respiratory DiseasesMay 29, 2025 | nasdaq.comMangoceuticals shares results from field studies on MGX-0024May 29, 2025 | finance.yahoo.comMangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 27, 2025 | globenewswire.comMangoceuticals, Inc. Terminates Agreements with Key PartnersMay 23, 2025 | tipranks.comSee More Headlines MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed this year? Mangoceuticals' stock was trading at $2.42 at the beginning of the year. Since then, MGRX shares have decreased by 19.8% and is now trading at $1.94. View the best growth stocks for 2025 here. How were Mangoceuticals' earnings last quarter? Mangoceuticals, Inc. (NASDAQ:MGRX) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($1.29) EPS for the quarter. The firm earned $0.11 million during the quarter. Mangoceuticals had a negative trailing twelve-month return on equity of 72.81% and a negative net margin of 2,191.76%. When did Mangoceuticals' stock split? Mangoceuticals's stock reverse split on Wednesday, October 16th 2024. The 1-15 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an IPO on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mangoceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mangoceuticals investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), MSP Recovery (LIFW), MSP Recovery (LIFW), Advanced Micro Devices (AMD). Company Calendar Last Earnings5/15/2025Today6/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryHealthcare Current SymbolNASDAQ:MGRX CIK1938046 Webwww.mangorx.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.71 million Net Margins-2,191.76% Pretax Margin-2,191.76% Return on Equity-72.81% Return on Assets-66.58% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$620 thousand Price / Sales16.18 Cash FlowN/A Price / Cash FlowN/A Book Value$4.30 per share Price / Book0.45Miscellaneous Outstanding Shares5,170,000Free Float4,342,000Market Cap$10.03 million OptionableNot Optionable Beta2.75 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:MGRX) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.